(Q43695088)

English

EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

scientific article published on 12 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

based on heuristic

inferred from title

author name string

R V Moerman

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

S Arends

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

P M Meiners

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

E Brouwer

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

F K L Spijkervet

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

F G M Kroese

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

A Vissink

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

H Bootsma

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

12 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

472-474

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203736

21 January 2018

Treatment of primary Sjögren syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203736

21 January 2018

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203736

21 January 2018

Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203736

21 January 2018

Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203736

21 January 2018

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203736

21 January 2018

Methods for assessing responsiveness: a critical review and recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203736

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2013-203736

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43695088&oldid=2102636885"